LCA is a secondary bile acid produced when intestinal microorganisms transform primary bile acids. It participates in bile acid metabolism and can influence cellular signaling, energy balance, and inflammation. At high concentrations, however, LCA has been linked to cholestasis, impaired bile flow, obstruction of bile ducts, hepatocyte injury, and cell death. This apparent contradiction has complicated efforts to explore LCA as a possible therapy. Earlier work had shown that LCA levels rise during caloric restriction, a dietary intervention associated with longer lifespan and improved metabolic health in several organisms.

Caloric restriction is thought to activate a network of metabolic responses that improve glucose handling, mitochondrial function, stress resistance, and tissue maintenance. LCA has been proposed as one of the circulating molecules that may help transmit some of these benefits. In animal studies, the bile acid has been associated with increased muscle NAD+ levels, improved grip strength and endurance in aged mice, and longer lifespan in nematodes and fruit flies. Yet the doses required to produce such effects must be distinguished from the much higher exposures known to damage the liver.

To investigate this dose boundary, a team led by Sheng-Cai Lin of Henan University and Xiamen University first studied obese mice. The animals received LCA in their drinking water at a concentration of 1 gram per liter, producing blood levels of approximately 1 micromole per liter. That exposure was designed to resemble the concentration observed during caloric restriction rather than the substantially higher levels used in toxicology experiments. After four weeks, the mice had lower hepatic triglyceride content, reduced fatty liver, and improved glucose metabolism.

The researchers also examined the molecular pathway behind the response. Liver-specific knockout mice lacking AMPKα did not receive the same metabolic benefits, implicating AMP-activated protein kinase as a central mediator. AMPK is an energy-sensing enzyme that becomes active when cellular energy supplies are limited. Once activated, it can suppress energy-intensive processes such as lipid synthesis while promoting fatty-acid oxidation and other pathways that help restore energy balance. The results indicate that low-dose LCA may improve liver metabolism through this energy-sensing system.

The safety picture changed sharply when the dose was increased. At 250 milligrams per kilogram per day, hepatic LCA concentrations reached about 14 micromoles per liter, and the mice developed clear signs of liver injury. This contrast provided direct evidence for a dose-dependent safety window: concentrations near those associated with caloric restriction appeared beneficial, while substantially higher exposure became toxic. The distinction is particularly important because bile acids can accumulate in the liver and exert effects that are not predicted simply by the administered dose.

The team next tested LCA in cynomolgus macaques with fatty liver. Translating doses from rodents to primates proved more complicated than expected. The monkeys rejected the formulation used in the mouse experiments, so the researchers developed a phospholipid-coated preparation suspended in fish oil. When they administered a mouse-equivalent dose calculated by body-surface-area conversion—9.6 milligrams per kilogram—the animals’ serum LCA concentrations rose above 6 micromoles per liter. Within one week, alanine aminotransferase and aspartate aminotransferase, enzymes commonly used to detect liver injury, increased significantly.

That result demonstrated why standard interspecies dose conversion can be unreliable for compounds whose absorption, metabolism, and circulation differ between animals. The researchers therefore conducted a dose-titration study in the macaques and identified two lower regimens: 0.25 milligrams per kilogram and 0.5 milligrams per kilogram, administered twice daily. These schedules maintained steady-state blood concentrations of approximately 0.8 to 1 micromole per liter, close to the target range observed in the mouse experiments, without producing biochemical evidence of liver damage.

After 13 weeks, macaques receiving either low-dose regimen showed significant histological improvement in hepatic steatosis, the abnormal accumulation of fat inside liver cells. Their body weight, blood lipids, and glucose levels remained stable, while ALT, AST, creatinine, and blood counts showed no treatment-related abnormalities. The findings do not establish that LCA is ready for human use, and the study involved early-stage fatty liver rather than advanced disease with severe hyperglycemia or hypertriglyceridemia. Longer studies will be needed to assess tissue distribution, sex-related differences, chronic toxicity, and responses in more advanced models. Nevertheless, the work provides the first reported evidence in a non-human primate that a carefully controlled, caloric-restriction-like concentration of LCA may alleviate fatty liver through hepatic AMPK activation without detectable toxicity.

Article Title: Lithocholic acid alleviates fatty liver in mice and non-human primate macaques

News Publication Date: 23-Jul-2026

Web References: https://doi.org/10.1093/lifemeta/loag023

References: Life Metabolism, DOI: 10.1093/lifemeta/loag023

Image Credits: Higher Education Press

Keywords: lithocholic acid, LCA, fatty liver, metabolic dysfunction-associated steatotic liver disease, caloric restriction, AMPK, bile acids, cynomolgus macaques, liver metabolism, hepatotoxicity

Acanthopanax trifoliatus, commonly known as the thorny ginseng, is a plant renowned for its diverse medicinal properties. It has been used for centuries in traditional medicine for its supposed health benefits, including anti-inflammatory, antioxidant, and immune-boosting effects. In the current study, researchers sought to investigate the specific hepatoprotective abilities of this plant, focusing on how its extracts could mitigate liver damage, a common health issue stemming from various causes such as alcohol consumption, viral infections, and metabolic disorders.

The backdrop of this research is critical, given the increasing prevalence of liver diseases worldwide. Conditions like non-alcoholic fatty liver disease (NAFLD), hepatitis, and cirrhosis continue to rise, prompting the need for effective therapeutic interventions. The authors recognize that traditional pharmacological therapies often come with significant side effects and limitations, thereby highlighting the potential of phytotherapy as a viable alternative. This study positioned Acanthopanax trifoliatus as a promising candidate for further exploration in the field of hepatoprotection.

In their methodology, the researchers utilized a HepG2 cell line, which is derived from human liver carcinoma and is commonly employed as a model for studying liver function and pathology. This cell line exhibits many characteristics of normal hepatocytes, making it an ideal candidate for assessing the therapeutic effects of various compounds. The study meticulously described the isolation and standardization of the leaf extract, ensuring that the active components were accurately identified and quantified.

The results yielded significant insights into the hepatoprotective properties of the Acanthopanax trifoliatus extract. Researchers observed that treatment with the standardized extract resulted in a marked reduction in hepatocyte apoptosis and necrosis, key indicators of liver damage. Additionally, the extract exhibited a capacity to modulate oxidative stress levels, a crucial factor in the progression of liver diseases. The authors noted that the extract appeared to enhance the cellular antioxidant defense mechanisms, potentially neutralizing the harmful effects of reactive oxygen species (ROS) that often contribute to tissue damage.

These findings pave the way for further investigation into the molecular mechanisms underlying the protective effects of Acanthopanax trifoliatus. The study suggests that the active phytochemicals within the extract may influence a range of cellular pathways associated with inflammation, apoptosis, and redox homeostasis. Understanding these mechanisms is vital, as it could lead to the development of new therapeutic agents that leverage the natural properties of this plant.

In addition to its direct hepatoprotective effects, the study also examined the potential of various formulations of the leaf extract. The researchers hypothesized that different methods of extraction could yield diverse biological activities and efficacy. By exploring these formulations, the authors aimed to identify the most effective means of harnessing the plant’s benefits, thereby contributing to the field of pharmaceutical development.

While the results are promising, the authors emphasize the necessity for further research. In vitro studies, such as those conducted using HepG2 cells, provide essential preliminary data, but their findings must eventually be validated through in vivo experiments. Animal models and human clinical trials will be crucial in confirming the efficacy and safety of Acanthopanax trifoliatus as a hepatoprotective therapy. Future studies will also need to address dosage optimization and potential interactions with other medications, particularly for populations with pre-existing health conditions.

The implications of this research extend beyond the lab, offering hope to millions affected by liver diseases. As public awareness of the importance of liver health increases, the demand for natural and less invasive treatment options is likely to grow. This study positions Acanthopanax trifoliatus as an intriguing candidate for future therapeutic strategies, possibly leading to new dietary supplements or herbal medications.

The overarching message of this research is clear: the exploration of natural products is a promising avenue for discovering novel hepatoprotective agents. With the ongoing challenges posed by liver diseases, the role of traditional medicinal plants as a source of innovation in modern medicine is more relevant than ever. Studies like those conducted by Sa-ngiamsuntorn and colleagues not only enhance our understanding of plant-based therapies but also inspire future generations of researchers to continue seeking answers within the rich tapestry of nature.

As the dialogue around plant-based medicinal research unfolds, it is critical that both the scientific community and the public stay informed. Knowledge sharing and collaborative efforts will be fundamental in advancing this field, making it imperative for researchers to communicate their findings effectively. In that respect, studies like this one serve to bridge the gap between ancient wisdom and modern scientific inquiry, creating a holistic approach to healthcare that respects and utilizes the resources nature provides.

The journey of Acanthopanax trifoliatus in the realm of hepatoprotection is just beginning. With its promising results, the study invites further exploration and encourages a broader acceptance of phytotherapy as a legitimate avenue for treating liver ailments. It stands as a testament to the need for ongoing research and development within this critical area of health.

As we await future findings and advancements stemming from this research, the potential for holistic health solutions is brighter than ever. The dialogue between traditional knowledge and contemporary science continues to evolve, with Acanthopanax trifoliatus at the forefront of this vital transformation. The meticulous study by Sa-ngiamsuntorn et al. underscores the importance of rigorous scientific research in validating the therapeutic claims of natural products, offering hope for more effective treatments for liver diseases in the future.

In conclusion, the exploration of Acanthopanax trifoliatus within a HepG2 model represents a significant step forward in the quest for hepatoprotective therapies. The encouraging results prompt further investigation into the plant’s potential, opening doors to innovative treatment options that harness the power of nature. As research progresses, we can anticipate a revitalized approach to liver health management that celebrates and incorporates the benefits of phytotherapy.

Subject of Research: Hepatoprotective effects of Acanthopanax trifoliatus standardized leaf extract

Article Title: Hepatoprotective effects of Acanthopanax trifoliatus standardized leaf extract and its formulations in a HepG2 model.

Article References:

Sa-ngiamsuntorn, K., Rojsanga, P., Ruenraroengsak, P. et al. Hepatoprotective effects of Acanthopanax trifoliatus standardized leaf extract and its formulations in a HepG2 model.
BMC Complement Med Ther 25, 319 (2025). https://doi.org/10.1186/s12906-025-05025-3

Image Credits: AI Generated

DOI: 10.1186/s12906-025-05025-3

Keywords: Hepatoprotective, Acanthopanax trifoliatus, liver health, medicinal plants, phytotherapy.

The collaboration marks a pivotal moment in medical research, co-led by Dr. Daohong Zhou from the University of Texas Health Science Center at San Antonio and Dr. Liya Pi from Tulane University. This intricate study provides compelling evidence that a new drug candidate has the potential to eliminate senescent cells, colloquially referred to as “zombie cells,” from the liver. This is crucial, as senescent cells accumulate in the liver in response to metabolic dysfunction, adversely influencing the trajectory of MASLD while significantly raising the risk of liver-related oncogenesis.

Dr. Zhou, who holds multiple academic and administrative positions at UT Health San Antonio, articulated the dire need for effective therapies in combating liver disease, especially in the context of MASLD and hepatocellular carcinoma, noting the disproportionate impact these conditions have on communities in San Antonio. By pioneering a drug that effectively targets senescent cells, the research offers hope for safer and more effective treatments to alleviate these debilitating diseases.

MASLD is intricately linked with obesity and diabetes, leading to excessive fat storage in the liver and initiating inflammation. The newly developed drug targets two specific proteins known as BCL-xl and BCL-2, which are instrumental in helping senescent cells avoid programmed cell death. By degrading these proteins, the drug candidates prompt the self-destruction of senescent cells, a process crucial for reducing liver fat accumulation, curtailing liver fibrosis, and potentially stymieing the progression to liver cancer.

The innovative approach taken in this study involved rigorous testing of the drug candidate in both in vitro cell cultures and in a mouse model designed to replicate MASLD. The results achieved were nothing short of remarkable, as the new drug displayed more potent effects when compared to prior senolytic treatments. Its selective targeting of senescent liver cells resulted in reduced liver damage and inhibited the growth of liver tumors, while notably sidestepping the toxic side effects often associated with existing therapies.

Dr. Zhou highlighted the overarching goal of this research: to pave the way for more selective and less harmful medicinal alternatives that can potentially address various liver diseases and age-related conditions. This emerging therapeutic strategy not only promises to enhance treatment outcomes for MASLD but also opens avenues for further exploration into the treatment of age-related afflictions that are compounded by the proliferation of senescent cells.

This significant research provides an encouraging perspective on the future of liver disease treatment, particularly in regions like San Antonio that confront elevated rates of obesity and diabetes. As such, it is imperative to amplify awareness about MASLD and the urgency for innovative treatment modalities that can slow its progression and prevent its severe complications, including liver cancer.

The particular relevance of this study arises from its implications for public health, given the substantial burden that liver diseases impose on communities. As diabetes and obesity rates continue to climb, addressing the roots of these metabolic disorders becomes increasingly pivotal. The integration of cutting-edge drug development focused on senolytic therapies may represent a significant component of a comprehensive strategy to tackle these chronic health issues.

The anticipation surrounding the potential of this drug candidate is further fueled by the scientific community’s interest in senescence and its effects on healthspan. As researchers continue to unravel the complexities of cellular aging, the linkage between metabolic disorders, inflammation, and senescent cell accumulation emerges as a critical area for future investigations. This research lays foundational groundwork for further studies aimed at elucidating the mechanisms by which senescent cells drive disease processes, particularly those related to the liver.

Moreover, the societal implications of this research transcend mere clinical outcomes, as it holds promise for alleviating the economic burden associated with chronic liver diseases. Effective treatments can lead to improved patient quality of life, reduced healthcare expenditures, and ultimately contribute to healthier communities. The positive trajectory of this research should embolden continued investment into innovative therapeutic approaches to combat MASLD and other related conditions.

As the scientific discourse progresses, maintaining engagement with ongoing studies in this domain is imperative. Researchers, practitioners, and policymakers must collaborate to ensure that breakthroughs translate into practice, bringing hope to those affected by liver diseases. The urgency for effective treatment options, especially in high-burden populations, cannot be overstated, as ongoing research endeavors aim to turn promise into reality.

In conclusion, this groundbreaking study signifies a decisive leap forward in the quest for effective treatments for metabolic dysfunction-associated liver diseases. By targeting the underlying mechanisms through which senescent cells exacerbate liver damage, the novel drug candidate uncovered in this research opens avenues for innovative therapies that potentially transform the landscape of liver disease management.

Subject of Research: Metabolic dysfunction-associated steatotic liver disease (MASLD)
Article Title: A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice
News Publication Date: 31-Jan-2025
Web References: Nature Aging Study
References: doi:10.1038/s43587-025-00811-7
Image Credits: (This section is not applicable)
Keywords: Liver, Liver cancer, Senescence, Steatohepatitis, Drug candidates, Obesity, Diabetes